Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF V600E - or BRAF InsT -Mutant Brain Tumors: PNOC002
JCO Precision Oncology · 2026
DOI: 10.1200/po-26-00558 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von Theodore Nicolaides und 15 weiteren Autor:innen. Beteiligte Einrichtung: Caris Life Sciences, Irving, TX. Hauptthemen laut MEDLINE: Antineoplastic Agents, Brain Neoplasms, Glioma, Neoplasm Recurrence, Local. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
Pediatric gliomas constitute the most prevalent central nervous system tumors in children, and aberrations in BRAF signaling contribute to their pathogenesis by disrupting the MAPK pathway. Targeted inhibition of this pathway using agents such as vemurafenib may hold therapeutic promise. Patients and Methods PNOC002 was a multicenter trial conducted through the Pediatric Neuro-Oncology Consortium in patients younger than 25 years with recurrent or progressive BRAF V600E -mutant brain tumors. This combined phase 0/1 study aimed to establish the recommended phase II dose (RP2D) and assess preliminary efficacy, including tumor growth trajectories and rebound (defined as ≥25% increase in lesion size within 6 months, usually within 3 months, of stopping therapy).
Results
Thirty-patients (range, 3-23 years) were treated at the RP2D of 550 mg/m 2 twice a day: 22 low-grade glioma (LGG) and 8 high-grade glioma (HGG). PFS at 6 months (PFS6) for the entire cohort was 80% (95% CI, 67 to 96). In patients with LGG, PFS6 was higher at 86% (95% CI, 73 to 100), compared with 63% (95% CI, 37 to 100) in patients with HGG. The best responses were stable disease (13 patients) and partial responses (13 patients). Four patients experienced PD, with three patients in the HGG cohort. Responsiveness varied by lesion type, with cystic lesions showing a larger and longer-lasting decrease in tumor size than solid lesions. Of 13 patients with LGG who discontinued treatment and had follow-up imaging, 3 (23%) experienced rebound within 78-97 days. The most common grade 3 adverse event was maculopapular rash (57%).
Conclusion
Vemurafenib showed efficacy in children with recurrent or progressive BRAF V600E -mutant brain tumors with acceptable toxicity. However, the rebound rate of 23% warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Caris Life Sciences, Irving, TX.
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Department of Neurology, Brain Tumor Center, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
- Department of Pediatrics, University of California, San Francisco, San Francisco, CA.
- Division of Hematology & Oncology, University of Alabama, Birmingham, AL.
- Phoenix Children's Hospital, University of Arizona College of Medicine, Phoenix, AZ.
ORCID-Profile: Theodore Nicolaides, Raoull Hoogendijk, Marie Jaeger-Krause, Girish Dhall, Amar Gajjar, Lindsay Kilburn, Sarah Leary, Jane Minturn, Nicholas Whipple, Mariam Aboian, Michael Prados, Annette M Molinaro, Sabine Mueller
Förderung
- NCI NIH HHS
Zitieren
APA
Nicolaides, T., Hoogendijk, R., Jaeger-Krause, M., Dhall, G., Goldman, S., Gajjar, A., Kilburn, L., Leary, S., Minturn, J., Whipple, N., Ramakrishnan, D., Long-Boyle, J., Aboian, M., Prados, M., Molinaro, A. M., & Mueller, S. (2026). Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF V600E - or BRAF InsT -Mutant Brain Tumors: PNOC002. JCO Precision Oncology. https://doi.org/10.1200/po-26-00558
Vancouver
Nicolaides T, Hoogendijk R, Jaeger-Krause M, Dhall G, Goldman S, Gajjar A, et al. Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF V600E - or BRAF InsT -Mutant Brain Tumors: PNOC002. JCO Precision Oncology. 2026. doi:10.1200/po-26-00558
BibTeX
@article{Nicolaides2026,
author = {Nicolaides, Theodore and Hoogendijk, Raoull and Jaeger-Krause, Marie and Dhall, Girish and Goldman, Stewart and Gajjar, Amar and Kilburn, Lindsay and Leary, Sarah and Minturn, Jane and Whipple, Nicholas and Ramakrishnan, Divya and Long-Boyle, Janel and Aboian, Mariam and Prados, Michael and Molinaro, Annette M and Mueller, Sabine},
title = {Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF V600E - or BRAF InsT -Mutant Brain Tumors: PNOC002},
journal = {JCO Precision Oncology},
year = {2026},
doi = {10.1200/po-26-00558}
}
EUVIMED